Survival and prognostic factors in patients with ovarian cancer

Obstetrics and Gynecology

Volumn 101, Issue 5, 2003, Pages 885-891

  Tingulstad, Solveig ^a   Skjeldestad, Finn Egil ^a   Halvorsen, Tore B ^a   Hagen, Bjørn ^a  

^a TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER INCIDENCE; CANCER PATIENT; CANCER REGISTRY; CANCER STAGING; CANCER SURVIVAL; CLINICAL STUDY; COMORBIDITY; COVARIANCE; FEMALE; GYNECOLOGY; HEALTH HAZARD; HISTOLOGY; HOSPITAL DISCHARGE; HUMAN; INCIDENCE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MEDICAL ASSESSMENT; MEDICAL SOCIETY; MORTALITY; MULTIVARIATE ANALYSIS; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NORWAY; OBSTETRICS; OVARY CANCER; PERIODICITY; POPULATION RESEARCH; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SURVIVAL RATE;

EID: 0038742791     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: 10.1016/s0029-7844(03)00123-6     Document Type: Article

References (37)

1. Look K. Epidemiology, etiology, and screening of ovarian cancer. In: Rubin SC, Sutton GP, eds. Ovarian cancer. 2nd ed. Philadelphia, Pennsylvania: Lippincott Williams & Wilkins, 2001:167-80.
2. The Cancer Registry of Norway. In: Annual report of the Cancer Registry. Oslo, Norway, 1998.
3. Pecorelli S, Benedet JL, Creasman WT, Shephard JH, Pettersson F. Annual report on the results of treatment in gynecological cancer. Vol 23. Oxford, United Kingdom: International Federation of Gynecology and Obstetrics, 1998.
4. Eisenhauer EA, Gore M, Neijt JP. Ovarian cancer: Should we be managing patients with good and bad prognostic factors in the same manner? Ann Oncol 1999;10 Suppl 1:9-15.
5. Clark TG, Stewart ME, Altman DG, Gabra H, Smyth JF. A prognostic model for ovarian cancer. Br J Cancer 2001; 85:944-52.
6. Griffith CT. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr 1975;42:101-4.
7. Lund B, Williamson P. Prognostic factors for overall survival in patients with advanced ovarian carcinoma. Ann Oncol 1991;2:281-7.
8. Høgberg T, Carstensen J, Simonsen E. Treatment results and prognostic factors in a population-based study of epithelial ovarian cancer. Gynecol Oncol 1993;48:38-49.
9. Tingulstad S, Halvorsen T, Norstein J, Hagen B, Skjeldestad FE. Completeness and accuracy of registration of ovarian cancer in the Norwegian Cancer Registry. Int J Cancer 2002;98:907-11.
10. Breslow NE, Day NE. Statistical methods in cancer research. Volume II—the design and analysis of cohort studies. IARC Sci Publ 1987;82:1-406.
11. Scully RE, Sobin LH, et al. Histological typing of ovarian tumors. 2nd ed. Geneva: WHO, 1999.
12. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chron Dis 1987;40:373-83.
13. Cox DR. Regression models and life-tables. JR Stat Soc 1972;34:187-220.
14. Junor EJ, Hole DJ, Gillis CR. Management of ovarian cancer: Referral to a multidisciplinary team matters. Br J Cancer 1994;70:363-70.
15. Bjørge T, Engeland A, Hansen S, Trope CG. Trends in the incidence of ovarian cancer and borderline tumors in Norway, 1954-1993. Int J Cancer 1997;71:780-6.
16. Levi F, Franceschi S, La Vecchia C, Ruzicka J, Gloor E, Randimbison L. Epidemiologic pathology of ovarian cancer from the Vaud Cancer Registry, Switzerland. Ann Oncol 1993;4:289-94.
17. Parazzini F, Franceschi S, La Vecchia C, Fasoli M. The epidemiology of ovarian cancer. Gynecol Oncol 1991;43:9-23.
18. Bjørge T, Engeland A, Hansen S, Trope CG. Prognosis of patients with ovarian cancer and borderline tumors diagnosed in Norway between 1954 and 1993. Int J Cancer 1998;75:663-70.
19. Malkasian GD, Melton LJ, O'Brien PC, Greene MH. Prognostic significance of histologic classification and grading of epithelial malignancies of the ovary. Am J Obstet Gynecol 1984;149:274-84.
20. Swenerton KD, Hislop TG, Spinelli J, LeRiche JC, Yang N, Boyes DA. Ovarian carcinoma: A multivariate analysis of prognostic factors. Obstet Gynecol 1985;65:264-70.
21. Balvert-Locht HR, Coebergh JWW, Hop WCJ, Brölmann HAM, Crommelin M, van Wijck DJAM, et al. Improved prognosis of ovarian cancer in the Netherlands during the period 1975-1985: A registry-based study. Gynecol Oncol 1991;42:3-8.
22. Brun JL, Feyler A, Chene G, Saurel J, Brun G, Hocke C. Long-term results and prognostic factors in patients with epithelial ovarian cancer. Gynecol Oncol 2000;78:21-7.
23. Baak JPA, Langley FA, Talerman A, Delemarre JFM. The prognostic variability of ovarian tumor grading by different pathologists. Gynecol Oncol 1987;27:166-72.
24. Stalsberg H, Abeler V, Blom GP, Bostad L, Skarland E, Westgaard G. Observer variation in histologic classification of malignant and borderline ovarian tumors. Hum Pathol 1988;19:1030-5.
25. Fleuren GJ, Nap M, Aalders JG, Trimbos B, De Bruijn HW. Explanation of the limited correlation between tumor CA125 content and serum CA125 antigen levels in patients with ovarian tumors. Cancer 1987;60:2437-42.
26. Tingulstad S, Hagen B, Skjeldestad FE, Halvorsen T, Nustad K, Onsrud M. The risk of malignancy index to evaluate potential ovarian cancers in local hospitals. Obstet Gynecol 1999;93:448-52.
27. Voest EE, Van Houwelingen JC, Neijt JP. A meta-analysis of prognostic factors in advanced ovarian cancer with median survival and overall survival (measured with log (relative risk)) as a main objective. Eur J Cancer Clin Oncol 1989;25:711-20.
28. Marsoni S, Torri V, Valsecchi MG, Belloni C, Bianchi U, Bolis G, et al. Prognostic factors in advanced epithelial ovarian cancer. Br J Cancer 1990;62:444-50.
29. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis. J Clin Oncol 2002;20:1248-59.
30. Hacker NF, Berek JS, Lagassa LD, Nieberg RK, Elashoff RM. Primary cytoreductive surgery for epithelial ovarian cancer. Obstet Gynecol 1983;61:413-20.
31. Bertelsen K. Tumor reduction surgery and long term survival in advanced ovarian cancer: A DACOVA study. Gynecol Oncol 1990;38:230-9.
32. Hoskins WJ, McGuire WP, Homesley HD, Creasman WT, Berman M, Ball H, et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 1994;170:974-80.
33. Heintz APM, Hacker NF, Berek JS, Rose TP, Munoz AK, Lagasse AD. Cytoreductive surgery in ovarian carcinoma: Feasibility and morbidity. Obstet Gynecol 1986;67:783-8.
34. Singh B, Bhaya M, Stern J, Roland JT, Zimbler M, Rosenfeld RM, et al. Validation of the Charlson comorbidity index in patients with head and neck cancer: A multiinstitutional study. Laryngoscope 1997;107:1469-75.
35. Extermann M, Overcash J, Lyman GH, Parr J, Balducci L. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol 1998;16:1582-7.
36. Rosenthal A, Jacobs I. Ovarian cancer screening. Semin Oncol 1998;25:315-25.
37. Jacobs IJ, Skates SJ, MacDonald N, Menon U, Rosenthal AN, Davies AP, et al. Screening for ovarian cancer: A pilot randomised controlled trial. Lancet 1999;353:1207-10.